Revance Therapeutics Inc (NAS:RVNC)
$ 2.67 -0.04 (-1.48%) Market Cap: 278.88 Mil Enterprise Value: 481.76 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 59/100

Q2 2023 Revance Therapeutics Inc Earnings Call Transcript

Aug 08, 2023 / 08:30PM GMT
Release Date Price: $21.99 (+1.34%)
Operator

Welcome to the Revance Therapeutics Second Quarter 2023 Financial Results and Corporate Update Conference Call. (Operator Instructions) As a reminder, this call is being recorded today, Tuesday, August 8, 2023.

I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations, Communications and ESG for Revance. Please go ahead.

Jessica Serra
Revance Therapeutics, Inc. - Head of IR & ESG

Thank you, operator. Joining us on the call today from Revance are Chief Executive Officer, Mark Foley; President, Dustin Sjuts; and Chief Financial Officer, Toby Schilke. During this conference call, management will make forward-looking statements, including statements related to 2023 guidance, cash flow breakeven, operating leverage, blockbuster potential and capital structure, our ability to draw on our debt, future revenue and expenses, the market, our growth potential, our CD approval and entry into therapeutics, our commercial success, account penetration, injector and consumer preferences and behavior, the efficacy and duration

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot